EP0874829A1 - Aminosäurederivate, ihre herstellung und verwendung als endothelinantagonisten - Google Patents

Aminosäurederivate, ihre herstellung und verwendung als endothelinantagonisten

Info

Publication number
EP0874829A1
EP0874829A1 EP96933398A EP96933398A EP0874829A1 EP 0874829 A1 EP0874829 A1 EP 0874829A1 EP 96933398 A EP96933398 A EP 96933398A EP 96933398 A EP96933398 A EP 96933398A EP 0874829 A1 EP0874829 A1 EP 0874829A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
phenyl
group
alkoxy
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96933398A
Other languages
German (de)
English (en)
French (fr)
Inventor
Dagmar Klinge
Wilhelm Amberg
Andreas Kling
Hartmut Riechers
Liliane Unger
Manfred Raschack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of EP0874829A1 publication Critical patent/EP0874829A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/58—Two sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Definitions

  • the present invention relates to new amino acid derivatives, their production and use
  • Endothelin is a 21 amino acid peptide that is synthesized and released by vascular endothelium.
  • Endothelin exists in three isoforms, ET-1, ET-2 and ET-3.
  • endothelin or "ET” means one or all isoforms of endothelin.
  • Endothelin is a potent vasoconstrictor and has a strong effect on vascular tone. This vasoconstriction is known to be caused by the binding of endothelin to its receptor (Nature, 332, 411-415, 1988; FEBS Letters, 231, 440-444, 1988 and Biochem. Biophys. Res. Commun., 154. 868-875, 1988).
  • Increased or abnormal release of endothelin causes persistent vascular contraction in peripheral, renal, and cerebral blood vessels, which can lead to disease.
  • the invention relates to amino acid derivatives of the formula I.
  • R represents a formyl group, a tetrazolyl, cyano, a group COOH or a radical which can be hydrolyzed to COOH.
  • R stands for a group
  • R 1 has the following meaning: a) hydrogen b) a succinylimidyl group c) a 5-membered heteroaromatic linked via a nitrogen atom, such as pyrrolyl, pyrazolylimidazolyl and triazolyl, which has one or two halogen atoms or one or two C 1 -C 4 - Can carry alkyl or one to two C 1 -C 4 alkoxy groups; d) R 1 also a group
  • R 1 is also a radical OR 10 , where R 10 is:
  • Hydrogen the cation of an alkali metal such as lithium, sodium, potassium or the cation of an alkaline earth metal such as calcium, magnesium and barium as well as physiologically compatible alkylammonium ion or the ammonium ion.
  • C 3 -C 8 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl,
  • C 1 -C 8 alkyl in particular C 1 -C 4 alkyl such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl;
  • CH 2 -phenyl which can be substituted by one or more of the following radicals: halogen, nitro, cyano,
  • R 10 can further be a phenyl radical which can carry one to five halogen atoms and / or one to three of the following radicals: nitro, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxy, C 1 -C 4 alkoxy, mercapto, C 1 -C 4 alkylthio, amino, C 1 -C 4 alkylamino, C 1 -C 4 dialkylamino; a 5-membered heteroaromatic linked via a nitrogen atom, containing one to three nitrogen atoms, which can carry one to two halogen atoms and / or one or two of the following radicals: C 1 -C 4 -alkyl,
  • C 1 -C 4 haloalkyl C 1 -C 4 alkoxy, phenyl, C 1 -C 4 haloalkoxy and / or C 1 -C 4 alkylthio.
  • the following may be mentioned in particular: 1-pyrazolyl, 3-methyl-1-pyrazolyl,
  • R 11 means:
  • R 1 is a residue
  • R 12 has the same meaning as R 11 ; h) furthermore R 1 can mean where R 13 and R 14 may be the same or different and have the following meanings: hydrogen, C 1 -C 7 alkyl, C 3 -C 7 cycloalkyl, C 3 -C 7 alkenyl, C 3 -C 7 alkynyl, Benzyl, phenyl, optionally substituted, as described above, or R 13 and R 14 together form an optionally substituted, for example by, closed to form a ring
  • C 1 -C 4 alkyl substituted C 4 -C 7 alkylene chain which has a heteroatom, for example oxygen, nitrogen or sulfur May contain as - (CH 2 ) 4 -, - (CH 2 ) 5 -, - (CH 2 ) 6 -. - (CH 2 ) 7 -, - (CH 2 ) 2 -O- (CH 2 ) 2 -, - (CH 2 ) 2 -S- (CH 2 ) 2 -, -CH 2 -NH- (CH 2 ) 2 -, - (CH 2 ) 2 -NH- (CH 2 ) 2 -; be a tetrazole or a nitrile.
  • W is nitrogen or C-NO 2 , furthermore W can stand for a CH group if one or more of the substituents R 2 , R 3 , R 15 and / or R 16 represent a nitro group;
  • R 2 is hydrogen, halogen, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, hydroxy, mercapto, C 1 -C 4 - Alkylthio, nitro, amino, C 1 -C 4 alkylamino or
  • R 2 can form a 5- or 6-membered alkylene or alkylidene ring with the adjacent carbon atom and X, in each of which one or two carbon atoms can be replaced by a hetero atom such as nitrogen, sulfur or oxygen and the one to can be substituted three times by the following radicals: halogen, nitro, cyano, hydroxy, mercapto, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 alkylthio, Amino, C 1 -C 3 alkylamino, C 1 -C 3 dialkylamino;
  • X is nitrogen or CR 15 wherein R 15 is hydrogen or
  • 6-membered ring can optionally be substituted one to three times with the following radicals;
  • Nitrogen in the 5-ring can also be substituted by a formyl or acetyl group; R 2 and R 3 may be the same or different; Y is nitrogen or CR 16 , where R 16 is hydrogen, C 1 -C 5 alkyl, C 1 -C 5 alkoxy, C 1 -C 5 alkylthio, nitro, phenyl, hydroxy, halogen, cyano, amino, C 1 - C 4 alkylamino, C 1 -C 4 dialkylamino or mercapto or CR 16 together with R 3 and its adjacent carbon atom is a 5- or
  • R 4 represents hydrogen, C 1 -C 7 alkyl, C 3 -C 7 cycloalkyl; or phenyl or naphthyl, which may be substituted by one or more of the following radicals;
  • Halogen nitro, cyano, hydroxy, C 1 -C 4 alkyl
  • R 4 can also mean a five- or six-membered heteroaromatic containing a nitrogen, sulfur or oxygen atom which can carry one or two of the following radicals: halogen, cyano, nitro, C 1 -C 4 - Alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, phenoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylamino or C 1 -C 4 dialkylamino; in addition, R 4 and R 5 can be phenyl groups which are ortho-stable via a direct bond, a methylene,
  • Sulfur atom or an SO 2 , NH or N-alkyl group are connected to one another;
  • R 5 has the meaning of C 1 -C 7 alkyl, C 3 -C 7 cycloalkyl or phenyl or naphthyl, which can be substituted by one to three of the following radicals; Halogen, nitro, cyano,
  • R 5 can be a five- or six-membered heteroaromatic containing a nitrogen, sulfur or oxygen atom, which can carry one or two of the following radicals: halogen, cyano, nitro, C 1 -C 4 -alkyl,
  • C 1 -C 4 haloalkyl C 1 -C 4 alkoxy, phenoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylamino or C 1 -C 4 dialkylamino;
  • R 5 together with R 4 can form a tricyclic compound as described above, and R 5 can also be an optionally substituted phenyl radical or heteroaromatic - as described above - which is ortho-standing with R 8 to one
  • 6-membered ring is linked, wherein Q must stand for a single bond and R 8 for a group CH-R 17 ;
  • R 6 is hydrogen, C 1 -C 4 alkyl or C 1 -C 4 haloalkyl
  • Z is a single bond, oxygen, sulfur, a sulfoxide or sulfonyl group
  • R 7 is hydrogen or C 1 -C 4 alkyl, C 2 -C 4 alkylene,
  • R 8 represents hydrogen, C 1 -C 4 alkyl, C 2 -C 4 alkylene, phenyl or benzyl, furthermore R 8 can be directly connected to R 5 , as described above, in which case R 8 represents a group CH -R 17 , in which R 17 is hydrogen, C 1 -C 4 alkyl, phenyl or phenyl mono- to trisubstituted by methoxy, or represents one of the following radicals.
  • the compounds and also the intermediates for their preparation II can have one or more asymmetrically substituted carbon atoms.
  • Such compounds can exist as pure enantiomers or pure diastereomers or as a mixture thereof.
  • the use of an enantiomerically pure compound as the active ingredient is preferred.
  • the invention furthermore relates to the use of the amino acid derivatives mentioned above for the production of medicaments, in particular for the production of inhibitors for endothelin receptors.
  • the compounds according to the invention are prepared by reacting an amino acid derivative II with a heterocycle derivative III in which R 17 is halogen or R 18 is SO 2 , where R 18 is C 1 -C 4 -alkyl, C 1 -C 4 - May be haloalkyl or phenyl.
  • R means a carboxylic acid ester or a carboxylic acid.
  • the reaction preferably takes place in an inert solvent with the addition of a base, as described in the literature e.g. in J. Am. Chem Soc. 1976, 98, 8472-8475 or J. Chem. Soc. Perkin Trans I, 1988, 691-696.
  • solvents or diluents examples include water, aliphatic, alicyclic and aromatic hydrocarbons, which may optionally be chlorinated, such as hexane, cyclohexane, petroleum ether, ligroin, benzene, toluene, xylene, methylene chloride, chloroform, carbon tetrachloride, ethyl chloride and trichlorethylene, ethers, such as Diisopropyl ether,
  • the reaction is preferably carried out in a temperature range between 0 ° C. and the boiling point of the solvent or solvent mixture.
  • an alkali or alkaline earth metal hydride such as sodium hydride, potassium hydride or calcium hydride
  • a carbonate such as alkali metal carbonate, e.g. Sodium or potassium carbonate
  • an alkali or alkaline earth metal hydroxide such as sodium or potassium hydroxide
  • an organometallic compound such as butyllithium or a
  • Alkali amide such as lithium diisopropylamide are used.
  • Compounds of formula II, insofar as they are not known, are also the subject of the invention. They can be manufactured in a known manner.
  • this reaction is carried out in a 2-phase mixture with a phase transfer catalyst under phase transfer conditions, for example in methylene chloride and 5-20% strength aqueous sodium hydroxide solution with a quaternary ammonium salt, such as, for example, tetra-n-butylammonium hydrogen sulfate.
  • a phase transfer catalyst under phase transfer conditions, for example in methylene chloride and 5-20% strength aqueous sodium hydroxide solution with a quaternary ammonium salt, such as, for example, tetra-n-butylammonium hydrogen sulfate.
  • K has the
  • the hydrolysis of VI to Ila can take place in a suitable solvent with inorganic or organic, strong acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, acetic acid, trifluoromethylsulfonic acid or trifluoroacetic acid of different concentrations.
  • Water, C 1 -C 4 alcohols, acetonitrile, diethyl ether, tetrahydrofuran, dioxane or toluene can be used as solvents.
  • the compounds IIb according to the invention in which Z is a bond, R 5 is an aromatic or heteroaromatic radical and R 6 is a C 1 -C 4 alkyl group are prepared by combining a suitable phosphonate compound VII with a carbonyl compound VIII in a Wittig-Horner Reaction to the ⁇ , ⁇ -unsaturated compound IX is implemented.
  • R 20 here means C 1 -C ⁇ -alkyl or benzyl.
  • Compounds X can be converted to hydrazino acid derivatives XII by known methods, as described, for example, in J. Am. Chem. Soc., 1986, 108 6395-6397.
  • Dialkylazodicarboxylate XI is used as amination reagent, where R 21 stands for 2,2-dimethylethyl or benzyl.
  • R 21 stands for benzyl
  • the conversion from XII to XIII can also take place by means of hydrogenolysis with hydrogen and a suitable catalyst, such as, for example, palladium on activated carbon, in different concentrations, for example 10% palladium on carbon.
  • ⁇ -hydrazinocarboxylic acid derivatives XIII can be treated with a suitable catalyst, e.g. Raney nickel, with hydrogen under pressure, e.g. 10-50 bar, to be reduced to the ⁇ -amino acid derivatives Ilb.
  • a suitable catalyst e.g. Raney nickel
  • hydrogen under pressure e.g. 10-50 bar
  • the compounds Ilb can also be prepared by reacting a compound XIV with a Grignard compound XV and hydrolyzing the product XVI to Ilb under the action of acid, as described analogously in Liebigs Ann., 1977, 1174-1182:
  • the protective group In the case of R 22 ⁇ hydrogen, the protective group must be removed by known methods hydrolytically, with acid addition, or hydrogenolytically with a suitable catalyst; and you get connection Ile in this way.
  • the compounds IIc according to the invention are reacted with III to give Ic.
  • the compounds XVII according to the invention can also be prepared by reacting known or, according to known methods, ⁇ , ⁇ -unsaturated carbonyl compounds XIX, for example according to J. Org. Chem., 1991, 56, 6744-6, with an amination reagent XX and a suitable catalyst .
  • the compounds Id according to the invention in which Q is a bond and R 8 is not hydrogen, can be prepared by converting an amino acid derivative IId (Q means a bond and R 8 is hydrogen) according to known methods, for example into an N-benzyloxycarbonyl derivative XXI and this
  • a strong base for example potassium tert-butoxide
  • an alkylating agent R 8 -K in which K is usually halogen or a sulfate radical.
  • the resulting derivative XXII can be deprotected by known methods for the amino compound Ile, for example by splitting off the benzyloxycarbonyl group with hydrogen with palladium / activated carbon catalysis in an inert solvent.
  • L has the meaning of halogen, OR 23 , where R 23 stands for one of the following radicals:
  • L can furthermore stand for azido, p.tolylsulfonyl, methylsulfonyl, trifluoromethylsulfonyl or can mean anhydride.
  • R 5 is linked to R 8
  • R 8 can be prepared from the tetrahydroisoquinoline derivatives Ilf, which in turn are derived from the amino acid derivatives Ild by reaction with aldehydes of structure XXIV under the action of acid, for example hydrochloric acid or sulfuric acid analogously to Synthesis, (1990) , Pp. 550-556, can be produced.
  • R is a carboxylic acid, a carboxylic acid salt or one to one
  • R 2 is hydrogen, halogen, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, nitro, C 1 -C 4 alkoxy, C 1 -C 5 alkylthio, cyano, amino, methylamino, hydroxy or dimethylamino;
  • W is nitrogen, C-NO 2 and also CH if at least one of the radicals R 2 , R 3 , R 15 and R 16 represents a nitro group;
  • X is nitrogen or CR 15 , where R 15 is hydrogen, C 1 -C 4 alkyl,
  • C 1 -C 4 alkoxy, nitro, cyano, halogen or phenyl or CR 15 forms a 5- or 6-membered alkylene or alkylidene ring with R 3 and the adjacent carbon atom, in which one or two carbon atoms are replaced by a hetero atom such as nitrogen, Oxygen or sulfur can be replaced and which can be substituted once or twice by a C 1 -C 3 alkyl (or C 1 -C 3 alkoxy group); Nitrogen in 5-membered ring can also be substituted by CHO or COCH 3 group; R 3 can have the same meaning as R 2 and can also form an optionally substituted 5- or 6-ring with X and the adjacent carbon atom, as described above; furthermore R 3 with the adjacent carbon atom and Y can be a 5- or
  • Form 6-membered alkylene or alkylidene ring in which one or two carbon atoms can be replaced by nitrogen, oxygen or sulfur and which can be substituted one to two times by a C 1 -C 3 alkyl or C 1 -C 3 alkoxy group and a nitrogen atom in a 5-membered ring can be substituted by a CHO or COCH 3 group;
  • R 4 has the meaning of hydrogen, C ⁇ -C 6 alkyl, C 3 -C 7 cycloalkyl or phenyl, which is replaced by one or more of the following
  • Radicals can be substituted: halogen, C 1 -C 4 alkyl,
  • R 4 and R 5 can denote phenyl groups which are connected to one another in the ortho position via a direct bond, a CH 2 group, a CH 2 -CH 2 group or an oxygen atom;
  • R 5 can have the same meaning as R 4 , except for hydrogen and C 1 -C 6 alkyl, in addition R 5 can mean phenyl which can be substituted exclusively or in addition to the abovementioned radicals by two radicals on adjacent carbon atoms, which together form a first , 3-dioxomethylene - or a 1,4-dioxoethylene group and with the adjacent carbon atoms a 5 or. Form a 6-membered ring;
  • R 6 is hydrogen or C 1 -C 4 alkyl
  • Z is a single bond, oxygen or sulfur
  • R 7 is hydrogen or C 1 -C 4 alkyl
  • Q is a single bond, a carbonyl group or an oxycarbonyl group
  • R 8 is hydrogen or C 1 -C 4 alkyl.
  • R is a carboxylic acid, a carboxylic acid salt or one to one
  • R 2 is hydrogen, chlorine, methyl, ethyl, CF 3 , nitro, methoxy,
  • X is nitrogen or CR 15 , wherein R 15 is hydrogen, methyl, nitro or cyano or CR 15 with R 3 and the adjacent one
  • Carbon atom forms a 5- or 6-membered alkylene or alkylidene ring, in which one carbon atom can be replaced by oxygen, and which can be substituted by a methyl or methoxy group;
  • the 5- or 6-membered alkylene or alkylidene ring can have the following structures;
  • R 3 can have the same meaning as R 2 and can also form an optionally substituted 5- or 6-ring with X and the adjacent carbon atom, as described above; furthermore, R 3 can form an optionally substituted 5-6-membered alkylene or alkylidene ring with the adjacent carbon atom, in which one or two carbon atoms can be replaced by nitrogen or oxygen and that by a methyl or methoxy group can be substituted; Examples of such
  • Alkylene or alkylidene rings are:
  • R 4 has the meaning of hydrogen, methyl, ethyl, n-propyl, 1-methylethyl, cyclohexyl, or phenyl, which can be substituted by one or two methoxy groups, furthermore R 4 and R 5 can mean phenyl groups which are ortho-stable via a direct Bond, a CH 2 or CH 2 -CH 2 group are connected to one another;
  • R 5 denotes cyclohexyl or phenyl, which can be substituted by phenyl, one to three methoxy groups, or exclusively or in addition to a methoxy group by two radicals on adjacent carbon atoms, which together form one
  • R 5 can be an optionally substituted phenyl ring which is ortho-standing with R 8 to a 6-membered Ring is linked when Q is a single bond and R 8 is a group CH-R 17 ;
  • R 6 is hydrogen, methyl, ethyl, n-propyl or 1-methylethyl:
  • R 7 is hydrogen or methyl
  • Q is a single bond, a carbonyl group or an oxycarbonyl group:
  • R 8 is hydrogen, methyl or 1,1-dimethylethyl
  • R 8 may be directly linked to R 5 , as described above, when R 8 represents a group CH-R 17 , wherein R 17 is hydrogen, methyl, ethyl, phenyl or phenyl mono- to trisubstituted with methoxy or one of the following Leftovers means:
  • the compounds of the present invention offer new therapeutic potential for the treatment of hypertension, pulmonary hypertension, myocardial infarction, angina pectoris, acute renal failure, renal insufficiency, cerebral vasospasm, cerebral ischemia, subarachnoid hemorrhage, migraine,
  • Atherosclerosis endotoxic shock, endotoxin-induced organ failure, intravascular coagulation, restenosis after angioplasty, benign prostate hyperplasia, ischemic and. Intoxication-related kidney failure or hypertension.
  • the ET A receptor-expressing CHO cells were grown in F 12 medium with 10% fetal calf serum, 1% glutamine, 100 U / ml penicillin and 0.2% streptomycin (Gibco BRL, Gaithersburg, MD, USA). After 48 h the cells were washed with PBS and incubated with 0.05% trypsin-containing PBS for 5 min. The mixture was then neutralized with F 12 medium and the cells were collected by centrifugation at 300 ⁇ g. To lyse the cells, the pellet was briefly washed with lysis buffer (5 mM Tris-HCl, pH 7.4 with 10% glycerol) and then incubated at 4 ° C. for 30 min at a concentration of 10 7 cells / ml lysis buffer. The membranes were centrifuged at 20,000 x g for 10 min and the pellet stored in liquid nitrogen.
  • lysis buffer 5 mM Tris-HCl, pH 7.4 with 10% glycerol
  • Guinea pig cerebellas were homogenized in the Potter-Elvejhem homogenizer and obtained by differential centrifugation at 1,000 ⁇ g for 10 min and repeated centrifugation of the supernatant at 20,000 ⁇ g for 10 min. Binding tests
  • the membranes were incubated in incubation buffer (50 mM Tris-HCl, pH 7.4 with 5 mM MnCl 2 , 40 ⁇ g / ml bacitracin and 0.2% BSA) in a concentration of 50 ⁇ g Protein suspended per test batch and at 25 ° C with 25 pM 125 J-ET ⁇
  • incubation buffer 50 mM Tris-HCl, pH 7.4 with 5 mM MnCl 2 , 40 ⁇ g / ml bacitracin and 0.2% BSA
  • buffer A 120 mM NaCl, 5 mM KCl, 1.5 mM MgCl 2 , 1 mM CaCl 2 , 25 mM HEPES, 10
  • the fluorescence signal of 2 ⁇ 10 5 cells per ml at Ex / Em 380/510 was continuously recorded at 30 ° C.
  • the test substances and after an incubation time of 3 min ET1 were added to the cells.
  • the maximum change in fluorescence was determined over 30 minutes.
  • the cells' response to ET1 without the addition of a test substance served as a control and was set to 100%. Testing the ET antagonists in vivo
  • test animals were given the test compounds i.v. 5 min before the ET1 administration. injected (1 ml / kg). To determine the ET antagonistic properties, the increase in blood pressure in the test animals was compared with that in the control animals.
  • the principle of the test is to inhibit the sudden cardiac death of the mouse caused by endothelin, which is probably caused by narrowing of the coronary arteries, by pretreatment with endothelin receptor antagonists. After intravenous injection of 10 nmol / kg endothelin in a volume of 5 ml / kg
  • the lethal endothelin-1 dose is checked in each case in a small animal collective. If the test substance is administered intravenously, the endothelin-1 injection, which is lethal in the reference group, is usually given 5 minutes afterwards. For other types of application, the default times are extended, possibly up to several hours.
  • the survival rate is documented and effective doses that protect 50% of the animals against endothelin cardiac death for 24 hours or longer (ED 50) are determined.
  • a K + contracture is first triggered on aortic segments of the rabbit. After washing, an endothelin dose-response curve is drawn up to the maximum. Potential endothelin antagonists are applied to other preparations in the same vessel 15 minutes before the endothelin dose-response curve begins. The effects of endothelin are expressed in% of the K + contracture. Effective endothelin antagonists shift the endothelin dose-response curve to the right.
  • the compounds according to the invention can be administered in the usual way orally or parenterally (subcutaneously, intravenously, intramuscularly, intraperitoneally). It can also be applied with vapors or sprays through the nasopharynx.
  • the dosage depends on the age, condition and weight of the patient and on the type of application. As a rule, the daily dose of active substance is between approximately 0.5 and 50 mg / kg body weight when administered orally and between approximately 0.1 and 10 mg / kg body weight when administered parenterally.
  • the new compounds can be used in the customary pharmaceutical application forms, solid or liquid, e.g. as tablets, film-coated tablets, capsules, powders, granules, dragees, suppositories, solutions, ointments, creams or sprays. These are manufactured in the usual way.
  • the active ingredients can be processed with the usual pharmaceutical auxiliaries such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retardants, antioxidants and / or propellants (see H. Sucker et al .: Pharmaceuticals Technology, Thieme-Verlag, Stuttgart, 1991).
  • the administration forms obtained in this way normally contain the active ingredient in an amount of 0.1 to 90% by weight.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP96933398A 1995-10-04 1996-09-26 Aminosäurederivate, ihre herstellung und verwendung als endothelinantagonisten Withdrawn EP0874829A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19536891 1995-10-04
DE19536891A DE19536891A1 (de) 1995-10-04 1995-10-04 Neue Aminosäurederivate, ihre Herstellung und Verwendung
PCT/EP1996/004205 WO1997012878A1 (de) 1995-10-04 1996-09-26 Aminosäurederivate, ihre herstellung und verwendung als endothelinantagonisten

Publications (1)

Publication Number Publication Date
EP0874829A1 true EP0874829A1 (de) 1998-11-04

Family

ID=7773950

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96933398A Withdrawn EP0874829A1 (de) 1995-10-04 1996-09-26 Aminosäurederivate, ihre herstellung und verwendung als endothelinantagonisten

Country Status (24)

Country Link
US (1) US6440975B1 (cs)
EP (1) EP0874829A1 (cs)
JP (1) JP2000500738A (cs)
KR (1) KR19990063998A (cs)
CN (1) CN1202890A (cs)
AU (1) AU713763B2 (cs)
BG (1) BG63389B1 (cs)
BR (1) BR9610821A (cs)
CA (1) CA2231500A1 (cs)
CO (1) CO4770961A1 (cs)
CZ (1) CZ104598A3 (cs)
DE (1) DE19536891A1 (cs)
HR (1) HRP960437A2 (cs)
HU (1) HUP9900085A3 (cs)
IL (1) IL123611A (cs)
MX (1) MX9801987A (cs)
MY (1) MY115211A (cs)
NO (1) NO311025B1 (cs)
NZ (1) NZ319595A (cs)
PL (1) PL326081A1 (cs)
SK (1) SK43098A3 (cs)
TR (1) TR199800623T2 (cs)
WO (1) WO1997012878A1 (cs)
ZA (1) ZA968304B (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
SK179899A3 (en) 1997-07-03 2001-12-03 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
DE60036918D1 (de) * 1999-01-22 2007-12-13 Elan Pharm Inc Verbindungen die die vla-4 vermittelte adhäsion von leukozyten inhibieren
US6900232B2 (en) 2000-06-15 2005-05-31 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
EP1341773A2 (en) * 2000-12-07 2003-09-10 Cv Therapeutics, Inc. Substituted 1,3,5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
EP1713793A4 (en) * 2004-02-04 2009-09-02 Smithkline Beecham Corp PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS
DE602006020754D1 (de) 2005-09-29 2011-04-28 Elan Pharm Inc Carbamatverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
ZA200803280B (en) 2005-09-29 2009-11-25 Elan Pharm Inc Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
MY151045A (en) 2006-02-27 2014-03-31 Elan Pharm Inc Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
CN1908183B (zh) * 2006-08-16 2010-09-29 上海奥利实业有限公司 具内皮素拮抗作用的天然蛋白的酶解混合肽
CA2756808A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-piperidine compounds
WO2010126914A1 (en) 2009-04-27 2010-11-04 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
MX381819B (es) 2014-08-04 2025-03-13 Nuevolution As Derivados de heterociclico opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias.
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
JP7746259B2 (ja) 2019-12-20 2025-09-30 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性の化合物
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4092150A (en) * 1976-08-27 1978-05-30 Fmc Corporation Herbicidal 5-pyrimidinecarbonitriles
EP0347811B1 (en) * 1988-06-20 1994-03-30 Kumiai Chemical Industry Co., Ltd. Alkanoic acid derivatives and herbicidal compositions
CA2053603A1 (en) * 1990-10-19 1992-04-20 Katsumasa Harada 3-alkoxyalkanoic acid derivative, process for preparing the same and herbicide using the same
DE4105518A1 (de) 1991-02-22 1992-08-27 Basf Ag Sulfonylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung
DE69226813T2 (de) 1991-06-07 1999-02-18 Ube Industries, Ltd., Ube, Yamaguchi Pyrimidin- oder Triazin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Herbizide
DE4411225A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5958934A (en) * 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9712878A1 *

Also Published As

Publication number Publication date
NO311025B1 (no) 2001-10-01
WO1997012878A1 (de) 1997-04-10
HUP9900085A2 (hu) 1999-04-28
TR199800623T2 (xx) 1998-07-21
MX9801987A (es) 1998-08-30
NO981522L (no) 1998-04-03
KR19990063998A (ko) 1999-07-26
CA2231500A1 (en) 1997-04-10
NO981522D0 (no) 1998-04-03
HRP960437A2 (en) 1998-04-30
CO4770961A1 (es) 1999-04-30
HUP9900085A3 (en) 2001-11-28
BG102362A (en) 1999-08-31
CZ104598A3 (cs) 1998-09-16
DE19536891A1 (de) 1997-04-10
PL326081A1 (en) 1998-08-17
ZA968304B (en) 1998-04-03
AU7214796A (en) 1997-04-28
MY115211A (en) 2003-04-30
US6440975B1 (en) 2002-08-27
IL123611A0 (en) 1998-10-30
SK43098A3 (en) 1998-11-04
BG63389B1 (bg) 2001-12-29
IL123611A (en) 2001-08-26
AU713763B2 (en) 1999-12-09
NZ319595A (en) 2001-03-30
CN1202890A (zh) 1998-12-23
JP2000500738A (ja) 2000-01-25
BR9610821A (pt) 1999-07-13

Similar Documents

Publication Publication Date Title
EP1110952B1 (de) Neue Carbonsäurederivate, ihre Herstellung und Verwendung
EP0874829A1 (de) Aminosäurederivate, ihre herstellung und verwendung als endothelinantagonisten
EP0892787B1 (de) Neue alpha-hydroxysäurederivate, ihre herstellung und verwendung
DE19636046A1 (de) Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
EP0752854B1 (de) Pyrimidin- oder triazincarbonsäurederivate zur verwendung als arzneimittel
EP0733052B1 (de) Bicyclen-derivate, ihre herstellung und verwendung
EP0892786B1 (de) Neue carbonsäurederivate, ihre herstellung und verwendung
EP0892788A1 (de) Neue carbonsäurederivate, ihre herstellung und verwendung
WO1998027070A1 (de) Heterozyklische carbonsäurederivate, ihre herstellung und verwendung als endothelinrezeptorantagonisten
EP0862550B1 (de) Neue carbonsäurederivate, ihre herstellung und verwendung
EP0994861A1 (de) NEUE $g(b)-AMINO UND $g(b)-AZIDOCARBONSÄUREDERIVATE, IHRE HERSTELLUNG UND VERWENDUNG ALS ENDOTHELINREZEPTORANTAGONISTEN
EP1037883A1 (de) NEUE HETEROCYCLISCH SUBSTITUIERTE $g(a)-HYDROXYCARBONSÄUREDERIVATE, IHRE HERSTELLUNG UND VERWENDUNG ALS ENDOTHELINREZEPTORANTAGONISTEN
DE19809144A1 (de) Neue unsymmetrisch substituierte Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶LAMBDA¶/ET¶B¶-Rezeptorantagonisten
EP1140867A1 (de) Neue beta-amido- und beta-sulfonamidocarbonsäurederivate, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
EP1196394A1 (de) Neue carbonsäurederivate mit 5,6 substituiertem pyrimidinring, ihre herstellung und verwendung als endothelin rezeptorantagonisten
EP1104410A1 (de) Neue carbonsäurederivate, die ketoseitenketten tragen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
DE19924892A1 (de) Neue Carbonsäurederivate mit arylsubstituierten Stickstoffheterocyclen, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten
DE4341666A1 (de) Substituierte Cycloalkancarbonsäure-Derivate, ihre Herstellung und Verwendung
DE19700884A1 (de) Heterozyklische Carbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980309

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 980309

17Q First examination report despatched

Effective date: 20000623

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBOTT GMBH & CO. KG

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050401